|
1
|
Pastorino U: Lung cancer screening. Br J
Cancer. 102:1681–1686. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kanzawa F, Matsushima Y, Nakano H, et al:
Antitumor activity of a new platinum compound (glycolate-o,o′)
diammineplatinum (II) (254-S), against non-small cell lung
carcinoma grown in a human tumor clonogenic assay system.
Anticancer Res. 8:323–327. 1998.
|
|
3
|
Suzumura Y, Kato T, Ueda R and Ota K:
Effect of treatment schedule on antitumor activity of glycolate-0,
0′-diammineplatinum (II), a new platinum derivative: comparison
with cis-diamminedichloroplatinum (II). Anticancer Res.
9:1083–1088. 1989.PubMed/NCBI
|
|
4
|
Hida S, Okada K and Yoshida O: Advantages
in combination chemotherapy using cisplatin and its analogues for
human testicular tumor xenografts. Jpn J Cancer Res. 81:425–430.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Koshiyama M, Kinezaki M, Uchida T and
Sumitomo M: Chemosensitivity testing of a novel platinum analog,
nedaplatin (254-S), in human gynecological carcinomas: a comparison
with cisplatin. Anticancer Res. 25:4499–4502. 2005.PubMed/NCBI
|
|
6
|
Kuruse K, Fukuoka M, et al: A phase II
clinical study of cis-diammine glycolato platinum, 254-S, for
primary lung cancer. Gan To Kagaku Ryoho. 19:879–884.
1992.PubMed/NCBI
|
|
7
|
Zheng J, Wang G, Yang GY, et al: Induction
chemotherapy with nedaplatin with 5-FU followed by
intensity-modulated radiotherapy concurrent with chemotherapy for
locoregionally advanced nasopharyngeal carcinoma. Jpn J Clin Oncol.
40:425–431. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Naito Y, Kubota K, Ohmatsu H, et al: Phase
II study of nedaplatin and docetaxel in patients with advanced
squamous cell carcinoma of the lung. Ann Oncol. 22:2471–2475. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Oshita F, Ohe M, Honda T, et al: Phase II
study of nedaplatin and irinotecan with concurrent thoracic
radiotherapy in patients with locally advanced non-small-cell lung
cancer. Br J Cancer. 103:1325–1330. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Osawa S, Furuta T, Sugimoto K, et al:
Prospective study of daily low-dose nedaplatin and continuous
5-fluorouracil infusion combined with radiation for the treatment
of esophageal squamous cell carcinoma. BMC Cancer. 9:4082009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jin J, Xu X, Wang F, et al: Second-line
combination chemotherapy with docetaxel and nedaplatin for
Cisplatin-pretreated refractory metastatic/recurrent esophageal
squamous cell carcinoma. J Thorac Oncol. 4:1017–1021. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kitamura H, Taguchi K, Kunishima Y, et al:
Paclitaxel, ifosfamide and nedaplatin as second-line treatment for
patients with metastatic urothelial carcinoma: a phase II study of
the SUOC group. Cancer Sci. 102:1171–1175. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yin M, Zhang H, Li H, et al: The toxicity
and long-term efficacy of nedaplatin and paclitaxel treatment as
neoadjuvant chemotherapy for locally advanced cervical cancer. J
Surg Oncol. 105:206–211. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sasaki Y, Saijo N and Tamura T: Comparison
of the antitumor activity of cisplatin and its derivatives with
special stress on the pharmacokinetics of active form of drugs in
the plasma determined by colony assay. Proc Am Soc Clin Oncol.
6:341987.
|
|
15
|
Furuse K, Fukuoka M, Asamoto H, et al: A
randomized comparative study of 254-S plus vindesine (VDS) vs.
cisplatin (CDDP) plus VDS in patients with advanced non-small cell
lung cancer (NSCLC). Gan To Kagaku Ryoho. 19:1019–1026.
1992.PubMed/NCBI
|
|
16
|
Guo JF, Zhang B, Wu F, et al: A phase Ⅱ
trial of docetaxel plus nedaplatin and 5-fluorouracil in treating
advanced esophageal carcinoma. Chin J Cancer. 29:348–352. 2010.
View Article : Google Scholar
|
|
17
|
Cancer Therapy Evaluation Program, .
Common Terminology Criteria for Adverse Events. Version 3.0. DCTD,
NCI, NIH, DHHS. 2006.
|
|
18
|
Ohe Y, Ohashi Y, Kubota K, et al:
Randomized phase III study of cisplatin plus irinotecan versus
carboplatin plus paclitaxel, cisplatin plus gemcitabine and
cisplatin plus vinorelbine for advanced non-small-cell lung cancer:
four-arm cooperative study in Japan. Ann Oncol. 18:317–323. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hotta K, Matsuo K, Ueoka H, Kiura K,
Tabata M and Tanimoto M: Meta-analysis of randomized clinical
trials comparing Cisplatin to Carboplatin in patients with advanced
non-small-cell lung cancer. J Clin Oncol. 22:3852–3859. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jiang J, Liang X, Zhou X, Huang R and Chu
Z: A meta-analysis of randomized controlled trials comparing
carboplatin-based to cisplatin-based chemotherapy in advanced
non-small cell lung cancer. Lung Cancer. 57:348–358. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ardizzoni A, Boni L, Tiseo M, et al:
Cisplatin- versus carboplatin-based chemotherapy in first-line
treatment of advanced non-small-cell lung cancer: an individual
patient data meta-analysis. J Natl Cancer Inst. 99:847–857. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cao KJ, Zhang AL, Ma WJ, Huang PY, Luo DH
and Xia WX: Nedaplatin or cisplatin combined with 5-fluorouracil
for treatment of stage III–IVa nasopharyngeal carcinoma: a
randomized controlled study. Zhonghua Zhong Liu Za Zhi. 33:50–52.
2011.PubMed/NCBI
|
|
23
|
Yamashita H, Nakagawa K, Tago M, et al:
Radiation therapy combined with cis-diammine-glycolatoplatinum
(nedaplatin) and 5-fluorouracil for Japanese stage II–IV esophageal
cancer compared with cisplatin plus 5-fluorouracil regimen: a
retrospective study. Dis Esophagus. 19:15–19. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Scotti V, Meattini I, Saieva C, et al:
Limited-stage small-cell lung cancer treated with early
chemo-radiotherapy: the impact of effective chemotherapy. Tumori.
98:53–59. 2012.PubMed/NCBI
|
|
25
|
Yang R, Cheung MC, Pedroso FE, Byrne MM,
Koniaris LG and Zimmers TA: Obesity and weight loss at presentation
of lung cancer are associated with opposite effects on survival. J
Surg Res. 170:e75–e83. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ota K, Oguma T and Shimamura K:
Pharmacokinetics of platinum in cancer patients following
intravenous infusion of cis-diammine (glycolato) platinum, 254-S.
Anticancer Res. 14:1383–1387. 1994.PubMed/NCBI
|
|
27
|
Yamamoto N, Tamura T, Kurata T, et al:
Dose-finding and pharmacokinetic study of nedaplatin in elderly
patients with advanced non-small cell lung cancer. Cancer Chemother
Pharmacol. 65:79–88. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Teramoto K, Asada Y, Ozaki Y, et al: phase
II study of docetaxel plus nedaplatin in patients with metastatic
non-small-cell lung cancer. Cancer Chemother Pharmacol. 70:531–537.
2012. View Article : Google Scholar : PubMed/NCBI
|
